Enrique Grande, One Oncology Madrid Program Director at Quironsalud, shared on X:
“Review in Cancer on the evolving role of perioperative systemic therapy in bladder cancer.
Two phase 3 trials of perioperative enfortumab vedotin + pembrolizumab improved EFS and OS vs previous standards of care, in a setting no longer defined by cisplatin eligibility.
Next steps discussed: additional therapeutic targets and response-guided treatment pathways.”
Title: The evolving role of perioperative systemic therapy in bladder cancer
Authors: Saad O. Atiq, Jonathan F. Anker, Eric J. Miller, Alexander B. Karol, Reza Mehrazin, John P. Sfakianos, Matthew D. Galsky
You can also read:
- Martin Ignacio Zapata Laguado: New Perspectives on Bladder Cancer Imaging and Management at EMUC26
- Muscle-Invasive Bladder Cancer: Outcomes of Patients Who Declined Radical Cystectomy
